SEK 41.90
+2.74 (+7.00%)
SEK · as of 2026-08-17 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where HNSA.ST is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
13 interventional · 3 observational · 8 with posted results
government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Long-term Follow-up Trial of Patients Previously Treated With Imlifidase Prior to Kidney Transplantation and a Non-comparative Transplanted Patient GroupNCT05937750Graft failure-free survival (%) up to 5 years after imlifidase enabled transplantation (imlifidase cohort only)Non-randomized · Open-label · Other | Phase 3 | Active, not recruiting | Drug: Imlifidase administered in the 20-HMedIdeS-19 (PAES) study · Other: Best available treatment administered in the 20-HMedIdeS-19 (PAES) study | Long Term Efficacy and Safety | 150 | 2030-04-30 | in 1,350 d | 2026-06-23 |
| Survival and Dialysis Independency in Highly Sensitized Patients After Desensitization With Imlifidase and Tx of KidneysNCT05714514observationalProportion of patients alive and free of dialysis at 3 years | — | Active, not recruiting | Drug: Imlifidase administered in the ConfIdeS study · Other: Best available treatment administered in the ConfIdeS study | Kidney Transplantation in Highly Sensitized Patients | 64 | 2027-12-31 | in 499 d | 2025-11-18 |
| Imlifidase Prior to Kidney Transplant in Highly Sensitised ChildrenNCT05753930Proportion of patients with conversion of a positive crossmatch test to negative within 24 hours after start of imlifidase treatmentOpen-label · Treatment | Phase 2 | Recruiting | Drug: Imlifidase | Kidney Transplantation in Highly Sensitized Patients | 10 | 2027-02-28 | in 193 d | 2026-08-18 |
| Efficacy and Safety in Imlifidase Desensitized Kidney Tx Patients, Including Two Non-Comparative Reference CohortsNCT05369975Graft failure-free survival 1 year after transplantation following imlifidase treatmentNon-randomized · Open-label · Treatment | Phase 3 | Completed | Drug: Imlifidase · Other: Normal Transplantation Routine | Kidney Transplantation in Highly Sensitized Patients | 113 | 2026-04-21actual | — | 2026-05-05 |
| A Study With Imlifidase in Anti-GBM DiseaseNCT05679401Renal function as evaluated by estimated glomerular filtration rate (eGFR) at 6 monthsRandomized · Open-label · Treatment | Phase 3 | Terminatedsponsor's stated reason: Company decision, not due to any safety reason. | Drug: Imlifidase, Cyclophosphamide (CYC), Glucocorticoids · Procedure: Plasma exchange (PLEX) | Anti-Glomerular Basement Membrane Disease, Anti-Glomerular Basement Membrane Antibody Disease, Goodpasture Syndrome, Good Pasture Syndrome | 50 | 2025-06-23actual | — | 2026-03-04 |
| Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney TxNCT04935177Mean estimated glomerular filtration rate (eGFR) at 12 monthsRandomized · Open-label · Treatment | Phase 3 | Completed | Drug: Imlifidase, IVIg, Anti-CD20 antibodies, Eculizumab · Procedure: PLEX · Other: Remain on wait list | Kidney Transplantation in Highly Sensitized Patients | 64 | 2025-06-20actual | — | 2026-04-30 |
| A Study of Imlifidase in Patients With Guillain-Barré SyndromeNCT03943589results2025-04-09Guillain Barré Syndrome Disability Score (GBS DS) - Time to Improve by at Least 1 GradeOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Imlifidase | Guillain-Barré Syndrome (GBS) | 30 | 2024-02-27actual | — | 2025-04-09 |
| A Study to Investigate DSA Rebound in Patients Treated With Imlifidase Prior to TransplantationNCT05049850results2025-03-17Proportion of Patients With DSA ReboundOpen-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Company decision, not due to any safety reason | Drug: Imlifidase | Kidney Transplantation in Highly Sensitized Patients | 3 | 2024-02-05actual | — | 2025-10-21 |
| An Long-term Follow-up Trial of Kidney Tx Patients Treated With Imlifidase or PE After an AMRNCT04711850results2025-05-11observationalOverall Graft Survival at Year 3Study Protocol ↗ · Statistical Analysis Plan ↗ | — | Terminatedsponsor's stated reason: This is an internal decision based on prioritisations and no safety issues have been raised during the trial. | Drug: Imlifidase | Kidney Transplant Rejection | 18 | 2023-03-30actual | — | 2025-05-28 |
| A Follow up Study of Patients Treated With Imlifidase Prior to Kidney TransplantationNCT03611621results2025-02-07observationalEvaluation of Graft Survival in Subjects Who Have Undergone Kidney Transplantation After Imlifidase Administration.Study Protocol ↗ · Statistical Analysis Plan ↗ | — | Completed | Drug: Imlifidase | Kidney Transplant Failure and Rejection | 31 | 2023-02-14actual | — | 2025-02-07 |
| An Efficacy and Safety Study of Imlifidase in Treatment of Antibody-Mediated Rejection in Kidney Transplant PatientsNCT03897205results2024-02-28Maximum Reduction in Donor Specific Antibodies (DSA) Level During the 5 Days Following the Start of TreatmentRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Imlifidase · Other: Plasma Exchange | Kidney Transplant Rejection | 30 | 2022-05-28actual | — | 2024-02-28 |
| A Phase II Study to Evaluate the Efficacy of IdeS to Desensitize Transplant Patients With a Positive Crossmatch TestNCT02790437results2021-05-20Number of Patients With Crossmatch Conversion (Positive to Negative)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: IdeS · Procedure: Kidney transplantation | Kidney Failure, Chronic | 19 | 2017-12-12actual | — | 2021-05-20 |
| IdeS in Asymptomatic Antibody-Mediated Thrombotic Thrombocytopenic Purpura (TTP) PatientsNCT02854059results2019-09-13Safety and Tolerability as Measured by Type, Frequency and Intensity of Adverse EventsNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Sponsor review of initial results demonstrates a non-favourable risk benefit | Biological: IdeS (0.25 mg/kg), IdeS (0.50 mg/kg) | Purpura, Thrombotic Thrombocytopenic | 2 | Jan 2017actual | — | 2019-09-13 |
| Study to Evaluate the Safety, Tolerability, Efficacy and PK of IdeS in Kidney TransplantationNCT02475551safetyOpen-label · Treatment | Phase 2 | Completed | Drug: IdeS | End Stage Kidney Disease | 10 | Oct 2016actual | — | 2018-01-08 |
| Phase II Study, Evaluation of Safety and Efficacy of IdeS in Chronic Kidney DiseaseNCT02224820results2016-05-23EfficacyOpen-label · Treatment | Phase 2 | Completed | Biological: IdeS | Chronic Kidney Disease | 8 | Feb 2015actual | — | 2017-03-03 |
| Safety Study on IdeS in Healthy VolounteersNCT01802697Safety as measured by adverse eventsRandomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: IdeS, Placebo | Healthy | 29 | Dec 2013actual | — | 2017-01-19 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19